INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
55 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.97%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
6
Increased
21
Reduced
11
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
DM
1
Deerfield Management
New York
|
$38.9M |
2 |
2
BlackRock
New York
|
$17.1M |
3 |
![]()
3
Adage Capital Partners
Boston,
Massachusetts
|
$21.6M |
4 |
CCM
4
CAAS Capital Management
New York
|
$3.52M |
5 |
5
Millennium Management
New York
|
$2.95M |
Top Sellers
1 |
NHAS
1
Novo Holdings A/S
Hellerup,
Denmark
|
$39M |
2 |
O
2
OrbiMed
New York
|
$0 |
3 |
YU
3
Yale University
New Haven,
Connecticut
|
$0 |
4 |
CA
4
CHI Advisors
New York
|
$18.4M |
5 |
5
D.E. Shaw & Co
New York
|
$0 |